ASHTON PAUL has a total of 21 patent applications. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, medical technology and biotechnology are NUVO RES AG, EUROGENE LTD and SOLARTIUM ENTPR LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 12 | |
#2 | United States | 9 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Medical technology | |
#3 | Biotechnology | |
#4 | Foods and drinks | |
#5 | Computer technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Object sterilising | |
#4 | Peptides | |
#5 | Enzymes | |
#6 | Implantable devices | |
#7 | Healthcare informatics | |
#8 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Ashton Paul | 21 |
#2 | Guo Hong | 9 |
#3 | Chen Jianbing | 7 |
#4 | Cynkowski Tadeusz | 6 |
#5 | Cynkowska Grazyna | 6 |
#6 | Smith Thomas J | 4 |
#7 | Canham Leigh T | 3 |
#8 | Barnett Christian | 2 |
#9 | Canham Leigh | 1 |
#10 | Nadarassan Dinesh | 1 |
Publication | Filing date | Title |
---|---|---|
US2016075776A1 | Compositions and Methods for Controlled Release of Agents | |
WO2011094431A1 | Sustained-release nsaid/hmg coa reductase inhibitor compositions | |
US2010278931A1 | Porous silicon drug-eluting particles | |
WO2005009480A2 | Implants containing codrugs | |
WO2004066980A2 | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |